Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...

The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...

LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...

Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Novo Nordisk (NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight loss.